Sputum

New Campaign Highlights How Certain Jobs Can Increase a Person's Risk for Lung Disease

Retrieved on: 
Tuesday, April 9, 2024
Pneumonia, Emphysema, Bronchitis, Disease, Tobacco, Agriculture, Risk, Urinary tract infection, Spirometry, Fatigue, Smoke, Quality of life, Sputum, Dust, Mucus, Smoking, Wheeze, American Lung Association, COPD, Air pollution, Workplace, Phlegm, Ageing, Mining, Nursing

CHICAGO, April 9, 2024 /PRNewswire/ -- Chronic obstructive pulmonary disease (COPD) impacts 11.7 million people living in the U.S. While smoking is a significant risk factor for the disease, long-term exposure to dust, chemicals, fumes and vapors from the workplace may also lead to COPD. To help people identify workplace risk factors and encourage them to speak with their healthcare provider if they are experiencing symptoms, the American Lung Association is launching a campaign to raise awareness for occupational COPD. 

Key Points: 
  • While smoking is a significant risk factor for the disease, long-term exposure to dust, chemicals, fumes and vapors from the workplace may also lead to COPD.
  • COPD, which includes chronic bronchitis and emphysema, is a long-term lung disease that makes it hard to breathe.
  • Many workplaces may expose workers to risk factors for COPD, but the leading job types that increase risk for chronic lung disease include agriculture, mining and manufacturing.
  • Early treatment of a chronic lung disease, including reducing the exposure, can help lead to better health outcomes.

Herbal medicinal product: Thymi herba and Primulae radixArray, C: ongoing call for scientific data

Retrieved on: 
Tuesday, March 12, 2024
Primula, Key, Committee, Monograph, Plant, Nausea, Glycerol, Date, Mouth, Safety, Common, Phlegm, Patient, Medicine, Herbal medicine, Sputum, Ethanol, Medicinal plants

Herbal medicinal product: Thymi herba and Primulae radixArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Thymi herba and Primulae radixArray, C: ongoing call for scientific data

bioAffinity Technologies News Update

Retrieved on: 
Wednesday, February 21, 2024
Oncology, Health, Biometrics, Health Technology, General Health, Biotechnology, BIAF, American Thoracic Society, Medicine, Sputum, Research, Fluid, Cole, Conference, Chronic obstructive pulmonary disease, Nursing care plan, Lung, BAL, ATS, Human, Associate, Patient, Lung cancer, Bronchoalveolar lavage, COPD, Evidence-based practice, Pharmaceutical industry

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.
  • Lung Innovations Network’s multidisciplinary team focuses on affordable, innovative and individualized care by incorporating new technologies and research into an evidence-based practice.
  • National Sales Director Dallas Coleman announced that Cole Koeppen has joined bioAffinity Technologies as Pulmonary Sales Executive for CyPath® Lung in North Texas.
  • Bansal’s experience as both clinician and researcher demonstrates his commitment to innovative healthcare and the best possible outcome for his patients,” bioAffinity Technologies President and CEO Maria Zannes said.

bioAffinity Technologies In The News

Retrieved on: 
Tuesday, January 30, 2024
Technology, Surgery, Medical Devices, General Health, Science, Genetics, Clinical Trials, FDA, Biotechnology, Health, Health Technology, Research, Software, Other Health, Radiology, Pharmaceutical, Oncology, Intelligence, Lung cancer, College, Therapy, Clinical Laboratory, Sputum, CLIA, BIAF, Laboratory, Artificial intelligence, TCPP, Patent, Lung, Accreditation, CAP, Porphyrin, Cancer, Malignancy, Medical imaging

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news.
  • Precision Pathology Laboratory Services (PPLS), a bioAffinity Technologies company, successfully passed the rigorous biannual inspection required for College of American Pathologists (CAP) accreditation.
  • ScienceSoft , which provides IT consulting and software development services to more than 1,200 clients around the globe, recently published a case study of its work with bioAffinity Technologies.
  • More than 1,000 people registered for Webull Corporate Connect’s recent investment webinar that featured bioAffinity Technologies ’ President and CEO Maria Zannes and two other healthcare executives.

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Webcast, Drug development, Disease, NESS, Safety, NYSE, Policy, Senior, Food, Cystic fibrosis, Plasma protein binding, H.262/MPEG-2 Part 2, Workforce, Sputum, Clinical trial, Mortality, Insurance, Patient, Research, Part, FDA, Pharmacokinetics, Bacteria, Novartis, Conference, Pseudomonas aeruginosa, FEV1, Communication, CFU, Dermatology, Physician, Psoriatic arthritis, Fast Track, Part Two, Pharmaceutical industry, Medical imaging, Cryptocurrency

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the third quarter ended September 30, 2023.

Key Points: 
  • and NESS ZIONA, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the third quarter ended September 30, 2023.
  • In addition, the U.S. Food and Drug Administration recently granted Fast Track designation for BX004, further underscoring the potential of this promising program.
  • Net loss for the third quarter of 2023 was $7.9 million, compared to $6.8 million for the same period in 2022.
  • Net cash used in operating activities for the nine months ended September 30, 2023, was $15.0 million, compared to $21.9 million for the same period in 2022.

CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024

Retrieved on: 
Thursday, November 30, 2023
Other Health, Research, Managed Care, General Health, Oncology, Medical Devices, Clinical Trials, Science, Biotechnology, Medical Supplies, Other Science, Health, Lung, BIAF, Current Procedural Terminology, PLA, Sputum, Physician, Disease, Clinical trial, CPT, Patient, CD19, LDT, TCPP, Calendar, American Medical Association, Data analysis, CMS, Lung cancer, Flow cytometry, Cancer, Malignancy, Medicare, CEACAM8, CD3, Biopsy, Health insurance, Medical imaging

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other lung diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.

Key Points: 
  • bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other lung diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.
  • For the calendar year 2024 Medicare Clinical Lab Fee Schedule, CMS finalized the panel’s recommendation for CyPath® Lung for purposes of payment by Medicare.
  • In November 2023, CMS finalized the 2024 payment determination for CPT 0406U, effective January 1, 2024.
  • “Actionable results from CyPath® Lung may help doctors and their patients determine appropriate next steps for suspected cases of lung cancer,” Ms. Zannes said.

Laboratory Testing and PCR Technology Lead the India Infectious Disease Diagnostics Market, Transforming Disease Detection and Management - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023
Health, Infectious Diseases, Pathogen, Laboratory, Research, Public health surveillance, RPA, Molecular biology, Infection, Parasitism, Biomarker, Contact tracing, Research and development, CRISPR, PCR, Disease, Sputum, Fungus, Virulence, LAMP, Whole genome sequencing, Artificial intelligence, Vaccination, Urine, NGS, Diagnosis, COVID-19, Medicine, WGS, Blood, Microscopy, Public, Gene expression, DNA, Vaccine, Pharmaceutical industry, Epidemiology

The India emerging infectious disease diagnostics market is set for substantial growth over the forecast period from 2023 to 2033.

Key Points: 
  • The India emerging infectious disease diagnostics market is set for substantial growth over the forecast period from 2023 to 2033.
  • The India emerging infectious disease diagnostics market is currently in an emerging phase.
  • The India emerging infectious disease diagnostics market plays a pivotal role in modern biotechnology, clinical diagnostics, and pathogen research.
  • The India emerging infectious disease diagnostics market is segmented into key categories:
    In FY2022, laboratory testing was the dominant application segment in the India emerging infectious disease diagnostics market.

Avelo, VIVOLTA, and BLINK Win €1.5M Eurostars Grant to Develop New Solution for Diagnosing Lower Respiratory Tract Infections

Retrieved on: 
Thursday, October 26, 2023
Biotechnology, Physical Therapy, Health, General Health, Pharmaceutical, Health Technology, Medical Devices, Research, Infectious Diseases, Science, COVID-19, Vivolta, Infection, PCR, Sputum, Saliva, Urinary tract infection, Collection, BLINK, Bronchoalveolar lavage, Patient, Diagnosis, Pharmaceutical industry, Medical device, Medical imaging, Avelo Airlines

The project will span two years and lay the foundation for market launch in 2027.

Key Points: 
  • The project will span two years and lay the foundation for market launch in 2027.
  • The solution will be the world’s first breath-based system capable of fast, accurate, and specific diagnosis of LRTIs, and will be simple-to-use for maximum adoption around the world.
  • Joining forces with VIVOLTA and BLINK will help us to develop and validate our AveloCollect breath sampling kit, which has the potential to revolutionize the field of respiratory medicine.
  • After adding the breath sample from the AveloCollect device, the Respirex cartridge can be rapidly analyzed in BLINK’s first-of-its-kind point-of-care analyzer, the BLINK ONE.

New Study Shows Longhorn Vaccines and Diagnostics’ PrimeStore Molecular Transport Medium Improves Tuberculosis Testing in Children

Retrieved on: 
Tuesday, August 22, 2023
Biotechnology, Pharmaceutical, Health, Veterinary, Vaccine, Sputum, DNA, Public, TB, GA, MTM, SOS, MD, Collection, Canadian International Council, International Union Against Tuberculosis and Lung Disease, Ultra, Diagnosis, Respiratory disease, Mycobacterium tuberculosis, Disease, Pharmaceutical industry, Furniture, Tuberculosis, Longhorn

The data were published in a recent edition of the peer-reviewed International Journal of Tuberculosis and Lung Disease (IJTLD).

Key Points: 
  • The data were published in a recent edition of the peer-reviewed International Journal of Tuberculosis and Lung Disease (IJTLD).
  • Globally, an estimated one million children develop TB annually, mostly in low-income countries.
  • Testing is essential to early interventional treatment, so the use of stool swabs in molecular transport media was examined as a non-invasive, cost-effective and safe testing method.
  • PS-MTM inactivates TB and stabilizes DNA without refrigerated sample transport, which eliminates the need for cold-chain transport and storage.

BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 9, 2023
Insurance, Communication, CFA, Cystic fibrosis, Data analysis, Patient, Cystic Fibrosis Foundation, Disease, NYSE, PIPE, Policy, Pharmacokinetics, CFU, Pseudomonas aeruginosa, Corporation, Bacteria, Treasurer, FDA, CF, Conference, Safety, International, Professional corporation, ECFC, Psoriatic arthritis, Mortality, Research, Therapy, FEV1, Sputum, Workforce, Drug development, Clinical trial, Urinary tract infection, Fast Track, Part, Plasma protein binding, NESS, Phage therapy, Poster, AD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Biogen, Pharmaceutical industry, Medical imaging, Cryptocurrency

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the second quarter ended June 30, 2023.

Key Points: 
  • and NESS ZIONA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the second quarter ended June 30, 2023.
  • “Our BX004 clinical program in cystic fibrosis (“CF”) continues to build significant momentum,” said Jonathan Solomon, Chief Executive Officer of BiomX.
  • Net loss for the second quarter of 2023 was $6.4 million, compared to $7.5 million for the same period in 2022.
  • BiomX management will host a conference call and webcast today at 8:00 am ET to report financial results and business updates for the second quarter of 2023.